gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder
September 07, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed...
electroCore to Participate at Upcoming Investor Conferences
September 06, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer,...
electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
August 05, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...
electroCore Announces Record Second Quarter 2022 Financial Results
August 04, 2022 16:05 ET
|
electroCore, Inc.
Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and 14% sequentially Company to host a conference call and webcast today, August 4, 2022 at 4:30 pm EDT ...
electroCore to Announce Second Quarter 2022 Financial Results on August 4
July 28, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
electroCore Provides Select Second Quarter 2022 Financial Guidance
July 12, 2022 08:00 ET
|
electroCore, Inc.
Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021June 30, 2022, cash and cash equivalents balance of approximately $26.6 million ROCKAWAY, N.J., July ...
electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome
July 07, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an...
electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
May 24, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus...
electroCore to Participate at Upcoming Investor Conferences
May 18, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...
electroCore Announces Record First Quarter 2022 Financial Results
May 05, 2022 16:00 ET
|
electroCore, Inc.
First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast today, May 5, 2022 at, 4:30 PM EDT ...